Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Other Operating Expenses (2016 - 2025)

Seres Therapeutics' Other Operating Expenses history spans 6 years, with the latest figure at $736000.0 for Q3 2025.

  • For Q3 2025, Other Operating Expenses fell 82.8% year-over-year to $736000.0; the TTM value through Sep 2025 reached $9.6 million, up 16.34%, while the annual FY2024 figure was $3.5 million, N/A changed from the prior year.
  • Other Operating Expenses for Q3 2025 was $736000.0 at Seres Therapeutics, up from $185000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $7.0 million in Q4 2023 and bottomed at -$12.1 million in Q3 2023.
  • The 5-year median for Other Operating Expenses is $1.0 million (2022), against an average of $913125.0.
  • The largest YoY upside for Other Operating Expenses was 2120.52% in 2023 against a maximum downside of 1255.76% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $605000.0 in 2021, then crashed by 157.19% to -$346000.0 in 2022, then surged by 2120.52% to $7.0 million in 2023, then fell by 6.67% to $6.5 million in 2024, then crashed by 88.72% to $736000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Other Operating Expenses are $736000.0 (Q3 2025), $185000.0 (Q2 2025), and $2.2 million (Q1 2025).